Currently, the company has seven products in its research pipeline, including the targeted anti-tumor drug max-4 project, which has got the USA FDA orphan drug qualification in 2018, and launched the clinical phase I trial of acute myeloid leukemia in both Australia and China.Based on the new targets and mechanisms found in the China and Australia phase I clinical study, phase I clinical trial of solid tumor was launched in China in 2019, and was awarded the "Major New Drug Creation" project of the country major science and technology special project in the same year.

  Another important project is the oral cancer immunotherapy drug max-1, which launched a phase I clinical trial in Australia in 2019. The main preclinical studies of the project included a comparison of head-to-head tumor inhibition rates with pd-l1 antibody Durvalumab and pd-1 antibody Pembrolizumab. And in antibody-sensitive tumor models,they are showing similar efficacy with antibody drugs. In the tumor model with antibody sensitivity, the efficacy is superior to that of antibody drugs. The results indicate that the antitumor spectrum is expected to be much wider than that of antibody drugs.
OUR TEAM Members of the management team have European and American degrees and many years of research and management experience in multinational pharmaceutical companies.
CONTACT US
Please leave us a message,
we will reply to you as soon as possible, thank you!
Currently, the company has seven products in its research pipeline, including the targeted anti-tumor drug max-4 project, which has got the us FDA orphan drug qualification in 2018, and launched the clinical phase I trial of acute myeloid leukemia in both Australia and China.Based on the new targets and mechanisms found in the China and Australia phase I clinical study, phase I clinical trial of solid tumor was launched in China in 2019, and was awarded the "Major New Drug Creation" project of the country major science and technology special project in the same year. Another important project is the oral cancer immunotherapy drug max-1, which launched a phase I clinical trial in Australia in 2019. The main preclinical studies of the project included a comparison of head-to-head tumor inhibition rates with pd-l1 antibody Durvalumab and pd-1 antibody Pembrolizumab. And in antibody-sensitive tumor models,thay are showing similar efficacy with antibody drugs. In the tumor model with antibody sensitivity, the efficacy is superior to that of antibody drugs. The results indicate that the antitumor spectrum is expected to be much wider than that of antibody drugs.
OUR TEAM Members of the management team have European and American degrees and many years of research and management experience in multinational pharmaceutical companies.